ArticleGeburtshilfe und Frauenheilkunde2012
Biomarkers in Breast Cancer - An Update.
Article in Geburtshilfe und Frauenheilkunde, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.BioMed research international · 2014Trial
- Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer.South Asian journal of cancer · 2023Article
- Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer.International journal of molecular sciences · 2022Review
- CmP signaling network unveils novel biomarkers for triple negative breast cancer in African American women.Cancer biomarkers : section A of Disease markers · 2022Article
- Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.Geburtshilfe und Frauenheilkunde · 2019Article
- Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer.Geburtshilfe und Frauenheilkunde · 2018Article
- Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.Geburtshilfe und Frauenheilkunde · 2018Article
- Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.Geburtshilfe und Frauenheilkunde · 2018Article
- Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.Geburtshilfe und Frauenheilkunde · 2015Article
- Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Geburtshilfe und Frauenheilkunde · 2015Article
- Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.Geburtshilfe und Frauenheilkunde · 2015Article
- Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.BMC cancer · 2014Article
- [Future of mammography-based imaging].Der Radiologe · 2014Article
- Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?BioMed research international · 2014Article
- Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry.BioMed research international · 2014Article
- Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma.BioMed research international · 2014Article
- Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.Geburtshilfe und Frauenheilkunde · 2013Article
- Assessment of University Gynaecology Clinics Based on Quality Reports.Geburtshilfe und Frauenheilkunde · 2013Article
- Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.Breast cancer research and treatment · 2013Article
- Epidemiology of Breast Cancer - Current Figures and Trends.Geburtshilfe und Frauenheilkunde · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapy of choice for breast cancer patients requiring adjuvant chemo- or radiotherapy is increasingly guided by the principle of weighing the individual effectiveness of the therapy against the associated side effects. This has only been made possible by the discovery and validation of modern biomarkers. In the last decades and in the last few years some biomarkers have been integrated in clinical practice and a number have been included in modern study concepts. The importance of biomarkers lies not merely in their prognostic value indicating the future course of disease but also in their use to predict patient response to therapy. Due to the many subgroups, mathematical models and computer-assisted analysis are increasingly being used to assess the prognostic information obtained from established clinical and histopathological factors. In addition to describing some recent computer programmes this overview will focus on established molecular markers which have already been extensively validated in clinical practice and on new molecular markers identified by genome-wide studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.